Prostatherm Prostate Shrinker uses non-invasive Electro-Magnetic Tumor Treating Fields (TTF), Far Infra-Red (FIR), Green Photonic Ray, Hyperthermia and Vibrational Frequencies in tumour treatment and prevention:
information at prostate_reduce.html
The new Prostatherm emits 5 different therapeutic energies. Price = $1800 USD
Benign prostatic hyperplasia (BPH), or the noncancerous enlargement
of the prostate gland, is a common condition associated with aging. While
the prostate grows throughout a mans lifetime, bothersome growth typically
begins at age 40, and by approximately age 60 more than half of men will
have experienced at least some symptoms of BPH; by age 80, up to 80% to 90%
of men become symptomatic. It is estimated that nearly 15 million men in
the United States and 30 million men worldwide experience symptoms of BPH;
of this number, an estimated 25% require pharmaceutical or surgical
treatment. Due to the aging of the population, the number of men with the
condition is expected to follow an upward trend. This presents a
significant unmet need for minimally invasive or less invasive BPH therapy
as a less costly, more tolerable, and comparatively safe and effective
alternative to drugs and invasive surgery, which carry greater risk of
undesirable or significant side effects and complications, including death.
While current economic conditions continue to restrain market growth, the
U.S. market for minimally invasive bariatric surgical devices is expected
to exhibit relatively good growth over the next 5 years. Valued at an
estimated $147.5 million in 2010, the U.S. minimally invasive benign
prostatic hyperplasia therapy systems market is expected to increase at a
compound annual rate of 2.4%, with sales reaching more than $166 million in
2015. The largest segment, laser BPH therapy, is expected to drive market
growth over the forecast periodexpanding at a comparatively higher rate of
4.6%at the expense of minimally invasive office-based therapies.
This dynamic market report from Medtech Insight includes analyses of
products, markets, competitors, and emerging technology and opportunities.
Topics in this report include transurethral microwave thermotherapy (TUMT);
transurethral needle ablation (TUNA); holmium laser ablation of the
prostate (HoLAP); photoselective vaporization of the prostate (PVP), or
Greenlight Laser Therapy; transurethral resection of the prostate (TURP);
and the only other totally non-invasive energy-based technology is the Biophysica Prostate
Shrinker. Medtech report is available at http://www.medtechinsight.com/ReportA458.html
Revive is an all-natural dietary supplement containing 15 special
ingredients targeted towards improving and sustaining normal prostate
function from Dr David Brownstein at www.medixselect.com
Supplements for the Prostate in one capsule from Dr Fred Prologic at
saw palmetto berry extract
cranberry works on bladder and kidney 1000
green tea extract
stinging nettle root
pygeum africanum bark
Zinc for inflammation and the Immune System
Hydrangea root powder
Selenium 0.2 mg
Vitamin D3 1000 IU
Vibration may help heal chronic wounds Posted: 01 Apr 2014 at The Watchers.
Our prostatherm has vibration as one of the energies included.
Wounds may heal more quickly if exposed to low-intensity vibration, report researchers at the University of Illinois at Chicago. The finding, in mice, may hold promise for the 18 million Americans who have type 2 diabetes, and especially the quarter of them who will eventually suffer from foot ulcers. Their wounds tend to heal slowly and can become chronic or worsen rapidly. Timothy Koh, UIC professor of kinesiology and nutrition in the UIC College of Applied Health Sciences, was intrigued by studies at Stony Brook University in New York that used very low-intensity signals to accelerate bone regeneration. "This technique is already in clinical trials to see if vibration can improve bone health and prevent osteoporosis," Koh said. Koh and his coworkers at UIC... Read more »
- Prostate Enlargement/BPH Health Center at http://men.webmd.com/prostate-enlargement-bph/benign-prostatic-hyperplasia-bph-topic-overview
- Will hyperthermia
conquer the elusive hypoxic cell? Implications of heat effects on
tumor and normal-tissue microcirculation. Dewhirst MW,
Ozimek EJ, Gross J, Cetas TC. Radiology. 1980 Dec;137(3):811-7.
Abstract: In tumor radiobiology, the hypoxic cell has become
especially important because of recent evidence of acute hypoxic
regions within experimental tumors. The impact of hyperthermia on the
development of acute hypoxia is discussed. Two experiments for
studying hyperthermia and hypoxia in tumors are presented. Knowledge
of the microenvironment of tumor cells will be necessary to understand
and improve tumor control.
- Harris AL. Hypoxia--a key regulatory factor in tumour
growth. Nature reviews. 2002;2:3847.
- Hockel M, Vaupel P. Tumor hypoxia: definitions and
current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute. 2001;93:266276. [PubMed]
- Vaupel P. Tumor microenvironmental physiology and its
implications for radiation oncology. Seminars
in radiation oncology. 2004;14:198206. [PubMed]
- Brizel DM, Scully SP, Harrelson JM, et al. Tumor
oxygenation predicts for the likelihood of distant metastases in human
soft tissue sarcoma. Cancer research. 1996;56:941943. [PubMed]
- Reinhold HS, Endrich B. Tumour microcirculation as a
target for hyperthermia. Int J Hyperthermia.
- Hall EJ, Roizin-Towle L. Biological effects of heat. Cancer research. 1984;44:4708s4713s. [PubMed]
- Vernon CC, Hand JW, Field SB, et al. Radiotherapy with
or without hyperthermia in the treatment of superficial localized
breast cancer: results from five randomized controlled trials.
International Collaborative Hyperthermia Group. International journal of radiation oncology,
biology, physics. 1996;35:731744.
- van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van
Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with
radiotherapy plus hyperthermia in locally advanced pelvic tumours: a
prospective, randomised, multicentre trial. Dutch Deep Hyperthermia
Group. Lancet. 2000;355:11191125. [PubMed]
- Harima Y, Nagata K, Harima K, Ostapenko VV, Tanaka Y,
Sawada S. A randomized clinical trial of radiation therapy versus
thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia. 2001;17:97105. [PubMed]
- van der Zee J, van Rhoon GC. Cervical cancer:
radiotherapy and hyperthermia. Int J
Hyperthermia. 2006;22:229234. [PubMed]
- Song CW, Park H, Griffin RJ. Improvement of tumor
oxygenation by mild hyperthermia. Radiation
research. 2001;155:515528. [PubMed]
- Shakil A, Osborn JL, Song CW. Changes in oxygenation
status and blood flow in a rat tumor model by mild temperature
hyperthermia. International journal of
radiation oncology, biology, physics. 1999;43:859865.
- Vujaskovic Z, Poulson JM, Gaskin AA, et al.
Temperature-dependent changes in physiologic parameters of spontaneous
canine soft tissue sarcomas after combined radiotherapy and
hyperthermia treatment. International
journal of radiation oncology, biology, physics. 2000;46:179185.
- Brizel DM, Scully SP, Harrelson JM, et al. Radiation
therapy and hyperthermia improve the oxygenation of human soft tissue
sarcomas. Cancer research. 1996;56:53475350. [PubMed]
- Vujaskovic Z, Rosen EL, Blackwell KL, et al. Ultrasound
guided pO2 measurement of breast cancer reoxygenation after
neoadjuvant chemotherapy and hyperthermia treatment. Int J Hyperthermia. 2003;19:498506. [PubMed]
- Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel
AJ. Dynamics of tumor hypoxia measured with bioreductive hypoxic cell
markers. Radiation research. 2007;167:127145. [PubMed]
- Ljungkvist AS, Bussink J, Kaanders JH, et al. Hypoxic
cell turnover in different solid tumor lines. International journal of radiation oncology,
biology, physics. 2005;62:11571168.
- 18. Ljungkvist AS, Bussink
J, Rijken PF, Raleigh JA, Denekamp J, Van Der Kogel AJ. Changes in
tumor hypoxia measured with a double hypoxic marker technique. International journal of radiation oncology,
biology, physics. 2000;48:15291538.
- Ljungkvist AS, Bussink J, Kaanders JH, Wiedenmann NE,
Vlasman R, van der Kogel AJ. Dynamics of hypoxia, proliferation and
apoptosis after irradiation in a murine tumor model. Radiation research. 2006;165:326336. [PubMed]
- Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells
by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer research. 1993;53:57215726. [PubMed]
- Kleiter MM, Thrall DE, Malarkey DE, et al. A comparison
of oral and intravenous pimonidazole in canine tumors using
intravenous CCI-103F as a control hypoxia marker. International journal of radiation oncology,
biology, physics. 2006;64:592602.
- Urano M, Gerweck LE, Epstein R, Cunningham M, Suit HD.
Response of a spontaneous murine tumor to hyperthermia: factors which
modify the thermal response in vivo. Radiation
research. 1980;83:312322. [PubMed]
- Shin KH, Diaz-Gonzalez JA, Russell J, et al. Detecting
changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther. 2007;6:7075. [PubMed]
- Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue
JA. Visualization of hypoxia in microscopic tumors by
immunofluorescent microscopy. Cancer
research. 2007;67:76467653. [PubMed]
- Song CW, Shakil A, Osborn JL, Iwata K. Tumour
oxygenation is increased by hyperthermia at mild temperatures. Int J Hyperthermia. 1996;12:367373. [PubMed]
- Horsman MR, Overgaard J. Can mild hyperthermia improve
tumour oxygenation? Int J
Hyperthermia. 1997;13:141147. [PubMed]
- Okajima K, Griffin RJ, Iwata K, Shakil A, Song CW.
Tumor oxygenation after mild-temperature hyperthermia in combination
with carbogen breathing: dependence on heat dose and tumor type. Radiation research. 1998;149:294299. [PubMed]
- Thrall DE, Larue SM, Pruitt AF, Case B, Dewhirst MW.
Changes in tumour oxygenation during fractionated hyperthermia and
radiation therapy in spontaneous canine sarcomas. Int J Hyperthermia. 2006;22:365373. [PubMed]
- Song CW. Modification of blood flow. In: Molls M,
Vauple P, editors. Blood perfusion and
microenvironment of human tumors. Berlin:
Springer-Verlag; 1998. pp. 193207.
- Song CW, Park HJ, Lee CK, Griffin R. Implications of
increased tumor blood flow and oxygenation caused by mild temperature
hyperthermia in tumor treatment. Int J
- The optimal combination of hyperthermia and
carbogen breathing to increase tumor oxygenation and radiation
response. Griffin RJ,
Okajima K, Song CW. Int J Radiat Oncol Biol Phys.
1998 Nov 1;42(4):865-
33. Br J Cancer Suppl.
34. Int J
Hyperthermia. 2006 Mar;22(2):93-115.
35. The effect of mild temperature hyperthermia on tumour hypoxia and
blood perfusion: relevance for radiotherapy, vascular targeting and
imaging. Sun X, Xing L, Ling CC,
Li GC.Int J Hyperthermia.
Res. 2001 Apr;155(4):515-28.
1. How The Heating Effect In Magnetic Hyperthermia Works As A Cancer Treatment in Medical News, 17 Jul 2013, When the temperature rises above 42ºC cells begin to die. This heating process has been demonstrated to reduce tumour size.
A Better Probe for Prostate Cancer Diagnosis,
two optical techniques January 11, 2012
treatment kills cancer cells: researchers at Johns Hopkins University
conclude heat therapy may be a viable treatment for testicular cancer. www.naturalnews.com/019772_heat_therapy_cancer_therapies.html#ixzz18IIpp88w
3.Prostate biopsy cause serious
bleeding and infection-related complications, causing hospitalizations and
death, Friday, September 23, 2011 at http://www.naturalnews.com/033660_prostate_biopsy.html
Monitoring the effect of mild hyperthermia on tumour
hypoxia by Cu-ATSM PET scanning. Myerson RJ, Singh AK, Bigott
HM, Cha B, Engelbach JA, Kim J, Lamoreaux WT, Moros E, Novak P, Sharp TL,
Straube W, Welch MJ, Xu M.
6. Tumour oxygenation is increased by hyperthermia at
mild temperatures. Song CW, Shakil A, Osborn JL, Iwata K.
Int J Hyperthermia. 1996 May-Jun;12(3):367-73.
Tumour oxygenation is increased by hyperthermia at
mild temperatures. 1996. Song CW, Shakil A, Osborn JL, Iwata K.
Int J Hyperthermia. 2009 Mar;25(2):91-5.
Can mild hyperthermia improve tumour oxygenation? Horsman MR,
Overgaard J. Int J Hyperthermia.
Tumour pO2 can be increased markedly by mild
hyperthermia. Iwata K, Shakil A, Hur WJ, Makepeace CM, Griffin
RJ, Song CW.
Strong synergy of heat and modulated electromagnetic
field in tumor cell killing. Andocs G, Renner H, Balogh L, Fonyad
L, Jakab C, Szasz A.
Strahlenther Onkol. 2009 Feb;185(2):120-6. Epub 2009 Feb 25.
12. Effect of hyperthermia on hypoxic cell fraction in
Song CW, Rhee JG, Levitt SH. Int J Radiat Oncol Biol Phys. 1982 May;8(5):851-6.
Changes in tumour oxygenation during fractionated hyperthermia and
radiation therapy in spontaneous canine sarcomas. Thrall DE,
Larue SM, Pruitt AF, Case B, Dewhirst MW. Int J
Hyperthermia. 2006 Aug;22(5):365-73.
Changes in tumor oxygenation after localized
microwave heating. Vaupel P, Otte J, Manz R. Prog Clin Biol Res. 1982;107:65-74.
Changes in tumor hypoxia induced by mild temperature
hyperthermia as assessed by dual-tracer immunohistochemistry. Sun X, Li XF,
Russell J, Xing L, Urano M, Li GC, Humm JL, Ling CC. Radiother
Oncol. 2008 Aug;88(2):269-76.
Epub 2008 Jun 5.
16.Changes in oxygenation status and blood flow in a rat
tumor model by mild temperature hyperthermia. Shakil A,
Osborn JL, Song CW. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):859-65.
Changes in tumor hypoxia
induced by mild temperature hyperthermia 4243°C. Hypoxia and low perfusion
contribute to malignant progression. MTH effectively improved oxygenation
and enhanced the response of tumors to radiotherapy, and improved local
tumor control and patient survival, Sun, X. Li, X. Russell, J. Ling, C at
269276. and at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612785/
Benign Prostatic Hyperplasia Therapy Systems Market (May 2011) at http://www.medtechinsight.com/ReportA458.html
Hyperthermia treatments at http://www.sciencenews.org/articles/20061014/bob10.asp
Prostate treatments Comprehensive study Special
to CNN.com at http://www.cnn.com/HEALTH/library/DS/00027.html
APPROVES NEW DEVICE TO TREAT ENLARGED PROSTATE. Microwaves to heat
and destroy excess prostate tissue athttp://www.fda.gov/bbs/topics/NEWS/NEW00534.html
U.S. Minimally Invasive Benign
Prostatic Hyperplasia Therapy Systems Market
23. BSD Medical Announces Successful Initiation of
Hyperthermia Cancer Treatment (cervical cancer) at http://www.qmed.com/news/bsd-medical-announces-fda-hde-marketing-approval-bsd-2000-hyperthermia-system
24. Tumour Treating Fields: FDA approves the treatment of brain tumors with electrical fields
called Tumour Treating Fields: Tests with 20 different tumour cell types
indicate that the devices can slow and reverse tumor growth by inhibiting
mitosis, the process by which cancerous cells divide and replicate. The
Novocure treatment involves placing pads onto the patient's skin that
creates a low intensity, alternating electric field within the tumor. The
electric field prevents the normal mitotic process, rapid division of
cancer cells and causes cancer cell death (apoptosis) prior to division
without harming healthy cells. The results from a 237-patient trial
indicated that Novocure treated patients achieved comparable median overall
survival times to patients treated with chemotherapy but had fewer side
effects, and reported an improved quality of life. Therapy is
administered continuously over many hours per day. Link to www.gizmag.com/treatment-of-brain-tumors-with-electrical-fields/21433/?utm_source=Gizmag+Subscribers&utm_campaign=8905741cfd-UA-2235360-4&utm_medium=email
Scientists destroy tumors in mice using light therapy
- Prostate Health News: 10
powerful nutrients that work together for ultimate prostate protection
biopsy complications soar, causing hospitalizations and death (12
times greater risk of dying compared to men who did not have
biopsies), September 23, 2011 at http://www.naturalnews.com/033660_prostate_biopsy.html
- Vibration benefits:
Additional Publications added March 21, 2014
- Tumor Treating Fields (TTF) therapy has been well researched and recently gained FDA approval for brain tumours.
- “An Electrical Awakening” by Helen Thomson, New Scientist, March 1, 2014, Issue No 2958
- “The Healing Spark: Electric Medicine” by Linda Geddes, Cover story in New Scientist, February 22, 2014, Issue No 2957
- “On résiste à l'invasion des armées; on ne résiste pas à l'invasion des idées”. No army can stop an idea whose time has come, Victor Hugo 1852.
- General Pre-Clinical Research
Kirson et al. “Disruption of Cancer Cell Replication by Alternating Electric Fields.” Cancer Research, May 1, 2004 64; 3288.
- Breast Cancer Feasibility Study1
Schneiderman et al. “Synergism between chemotherapy and alternating electric fields (TTFields) in cancer cell proliferation inhibition and solid tumor treatment.” Poster presented at AACR Annual Meeting, April 12-16, 2008.
- Solid Tumor Feasibility Study
Salzberg et al. “A Pilot Study with Very Low-Intensity, Intermediate-Frequency Electric Fields in Patients with Locally Advanced and/or Metastatic Solid Tumors.” Onkologie 2008;31:362-365
- TTF Therapy Synergism with Chemotherapy Pre-Clinical Research
Kirson et al. “Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)”. BMC Medical Physics, January 8, 2009, Vol. 9:1.
- Metastatic Tumor Pre-Clinical Research
Kirson et al. “Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs.” Clinical and Experimental Metastasis, Volume 26, Number 7, 633-640.
- Multi-Drug Resistant Pre-Clinical Research:
Schneiderman et al. “TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.” BMC Cancer 2010, Vol. 10: 229.
- Kinetic Modeling of Time to TTF Effect in Solid Tumors:
Kirson, E.D., et al., "Modeling tumor growth kinetics and its implications for TTFields treatment planning" in The 2010 SNO Scientific Meeting and Education Day. 2010: Montreal, Canada.
- TTF Therapy Review
- Pless, M, et al., “Tumor treating fields: concept, evidence and future.” Expert Opin Investig Drugs. 2011 Aug;20(8):1099-106.
- Kirson et al. “Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.” Proceedings of the National Academy of Sciences, June 12, 2007 vol. 104 no. 24 10152-10157.
Newly Diagnosed Glioblastoma Brain Tumors1
- Kirson et al. “Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields).” BMC Medical Physics January 8, 2009, 9:1.
- Pless et al. “A phase II study of tumor treating fields (TTFields) in combination with pemetrexed for advanced non small cell lung cancer (NSCLC).” Ann Oncol (2010) 21(suppl 8): viii122-viii161.
- Weinberg et al. “A phase I study of Tumor Treating Fields (TTFields) in combination with pemetrexed for pretreated advanced non small cell lung cancer.” Poster Presented at European Respiratory Society Annual Congress, September 18-22, 2010.